Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-02-16
1996-11-26
Gerstl, Robert
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514374, 514400, 514427, 514438, A61K 31557
Patent
active
055786189
ABSTRACT:
The invention relates to ophthalmological compositions for topical treatment of glaucoma or ocular hypertension comprising an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGD, PGE or PGF, in which the omega chain contains a ring structure, in an ophthalmologically compatible carrier. The invention further relates to the preparation of said compositions and their use for treatment of glaucoma or ocular hypertension.
REFERENCES:
patent: 3956284 (1976-05-01), Hess et al.
patent: 3962312 (1976-06-01), Hayashi et al.
patent: 3987087 (1976-10-01), Bundy
patent: 4001300 (1977-01-01), Axen
patent: 4011262 (1977-03-01), Hess et al.
patent: 4061865 (1977-12-01), Hayashi et al.
patent: 4115586 (1976-09-01), Miller, Jr.
patent: 4116988 (1978-09-01), Nelson
patent: 4117119 (1978-09-01), Kurono et al.
patent: 4128713 (1978-12-01), Schneider
patent: 4131738 (1978-12-01), Smith
patent: 4599353 (1986-07-01), Bito
patent: 4820728 (1989-04-01), Collins et al.
patent: 4824857 (1989-04-01), Goh et al.
patent: 4883819 (1989-11-01), Bito
patent: 5001153 (1991-03-01), Ueno et al.
patent: 5057621 (1991-10-01), Cooper et al.
patent: 5151444 (1992-09-01), Ueno et al.
patent: 5166178 (1992-11-01), Ueno
patent: 5194429 (1993-03-01), Ueno
Bill A. (1975) "Blood Circulation and fluid dynamics in the eye". Physiol. Rew. 55:383-417.
Bito L. Z., Draga A., Blanco D. J., Camras C. B. (1983) "Long Term Maintenzance of Reduced intraocular Pressure by Daily or Twice Daily Topical Application of Prostaglandins to Cat or Rhesus Monk,ey Eyes" Invest. Ophthalmol. Vis. Sci. 24:312-319.
Bito, Baroody and Miranda (1987): Eicosanoids as a new class of ocular Hypotensive agents. The apparent therapeutic advantage of derived Prostaglandins of the A and B type as compared with primary prostaglandins of the E, F and D types", Experimental Eye Research, 44:825.
Bito, L. Z., Camras C. B., Gum G. G. and Resul B (1989), "The Ocular Hypotensive Effects and Side Effects of Prostaglandins on the Eyes of Experimental Animals" Progress in Clinical and Biological Research 312 Ed. L. Z. Bito and Johan Stjernschantz, A. R. Liss, Inc., New York.
Burke et al., "Prostaglandin F.sub.2.alpha. Effects on Rabbit IOP Negatively Correlate with Classical PGF.sub.2.alpha. -Receptor Stimulation Presented at ARVO annual meeting in Florida May 1-6, 1988.
Bundy, Chem Abst. 90:168141d, 1979.
Camras C. B., Bito L. Z. (1981). Reduction of intraocular pressure in normal and glaucomatous primate (Aotus trivirgatus) eyes by topically applied prostaglandin F.sub.2.alpha.. "Curr Eyes Res" 1:205-209.
Camras, C. B., Podos S. M., Rosenthal J. S., Lee P. Y., Severin C. H. (1987a). Multiple dosing of prostaglandin F.sub.2.alpha. or epinephrine on cynomologus monkey eyes. I. Aqueous humor dynamics. Invest Ophthalmol Vis Sci 28:463-469.
Camras C. B., Bito L. Z. and Eakins K. E. (1977): "Reduction of intraocular Pressure by prostaglandins applied to the eyes of concious rabbits", Invest Ophthalmol Vis. Sci, 16:1125.
Camras, C. B., Bhuyan K. C., Podos S. M., Bhuyan D. K. Master R. W. P. (1987b) "Multiple Dosing of Prostaglandin F.sub.2.alpha. or epinephrine on cynomologus mokey eyes. II. Slitlamp biomicroscopy, aqueous humor analysis, and fluorescein angiography." Invest. Ophthalmol. Vis. Sci. 28:921-926.
Camras, C. B., Siebold E. C., Lustgarten J. S., Serle J. B., Frisch S. C., Podos S. M., Bito L. Z. (1988) "Reduction of IOP by prostaglandin F.sub.2.alpha. -1-isopropyl ester topically applied in glaucoma patients", Ophthalmology 95(Suppl.) 129 [This article is referrenced in the specification, and was raised as prior art in an opposition to Australian patent application 625096, which is related to the instant application. However, we have been unable to locate a copy of this article].
Crawford K., Kaufman P. L. and True Gabel, B. A. (1987), "Pilocarpine antagonizes PGF.sub.2.alpha. -induced ocular hypotension: Evidence for enhancement of uveoscleral outflow of PGF.sub.2.alpha.," Invest Ophthalmol. Vis. Sci. (Supp.) ARVO Abstracts 11.
Crawford, K. and Kaufman, P. L., (1987) "Pilocarpine antagonizes Prostaglandin F.sub.2.alpha. -Induced Ocular Hypotension in Monkeys" Arch. Ophthamology 105 112.
Flach a. J., Elisason J. A. (1988). "Topical prostaglandin E.sub.2 effects on normal human intraocular pressure. J. Ocu. Pharmacol 4:13-18.
Gabelt, B. and Kaufman, P. L., (1989) "Prostaglandin F.sub.2.alpha. Increases Uvelscleral Outflow in the Cynomologus Monkey", Exp. Eye Res. 49 389-402.
Giuffr e G. (1985). "The effects of prostaglandin F.sub.2.alpha. in the human eye." Graefes Arch Clin. Exp. Ophthalmol 222:139-141.
Goldberg I., Kolker A. E., Kass M. A. and Becker B. (1980) "Dipivefrin: current concepts", Australia J. Ophthalmol., 8:147.
Granstrom, E., (1975) "Metabolism of 17-Phenyl-18,19,20-Trinor-Prostaglandin F.sub.2.alpha. in the Cynomolgus Monkey and the Human Female", Prostaglandins 9:19-45.
Kass, M. A., Posos, s. M., Moses, R. A., and Becker B. (1972): Prostaglandin E1 and aqueous humor dynamics", Invest. Ophthalmol. 11:1022.
Kass, M. A., Mandell Al, Goldberg I., Paine J. M. and Becker B. (1979) "Dipivefrin and epinephrine treatment of elevated intraocular pressure: A comparative study", Arch Ophthalmol. 97:1865.
Kaufman P. L. (1986) "Effects on intracamerally infused prostaglandins on outflow facility in cynomolgus monkey eyes with intact or retrodisplaced ciliary muscle." Exp. Eye Res. 43:819-827.
Kerstetter J. R., Brubaker R. F., Wilson S. E. and Kullerstrand B. S. (1987): "Prostaglandin F2 alpha 1-isopropyl ester effects on aqueous humor dynamics in human subjects", Invest Ophthalmol Vis Sci Suppl, 28:266. Kerstetter J. R., Brubaker R. F., Wilson S. E. and Kullerstrand L. (1988) "prostaglandin F2.sub..alpha. -1-isopropylester Lowers Intracolor Pressure Without Decreasing Aqueous Humor Flow". Am. J. Ophthalmology 105:30-34.
Kirk-Othmar "Encyclopedia of Chemical Technology", 3d Ed. Supplement vol. 711-752 (1984).
Lee, P-Y, Shae H., XZu L., Qu C-K (1988). The effect of prostaglandin F.sub.2.alpha. on intraocular pressure in normotensive human subjects," Invest. Ophthalmol. Vis. Sci. 29:1474-1477.
Miller, "Biological Activities of 17-phenyl-18, 19, 20-trinoprostaglandins", Prostaglandins 9 9-18 (1975).
Nilsson S. F. E., Stjernschantz J. and Bill A. (1987) "PGF.sub.2.alpha. increase uveoscleral outflow. Invest. Ophthalmol Vis. Sci. Suppl. 284.
Ritch, Shields and Krupin (1989): "The Glaucomas", C. V. Mosby, p. 561.
Starr, M. S. (1971) "Further studies on the effect of prostaglandin on intraocular pressure in the rabbit, Exp. Eye, Res. 11:170.
Villumsen J., Alm A., Soderstrom M., (1989) "Prostaglandin F.sub.2.alpha. -isopropylester Eye Drops: Effect on Intraocular Pressure in Open Angle Glaucoma". Brit. J. Ophthalmology 73, 975-79.
Villumsen J. Alm A. (1989) "Prostaglandin F.sub.2.alpha. isopropylester eye drops. Effects in normal human eyes." Br. J. Ophthalmol. 73:419-426.
Villumsen J. and Alm A. (1987): "The effect of prostaglandin F.sub.2.alpha. eye drops in open angle glaucoma", Invest Ophthalmol. Vis. Sci. 28:378.
Wang R-F., Cmamras C. B., Lee P-Y., Podos s. M. and Bito L. Z. (1987) "The ocular hypotensive effects of Prostaglandins F2.sub..alpha. isopropyl ester and A2 in glautomatous monkeys Invest Ophthalmol Vis Sci ARVO Supl. 28:266.
YUankee, Chem Abst. 88:62048, 1978.
Woodward et al., "Prostaglandin F.sub.2.alpha. Effects on IOP Negatively Correlate with Classical PGF.sub.2.alpha. -Receptor Stimulation Presented in Eightly International Congress of Eye Research in San Francisco Sep. 4-8, 1988.
Woodward et al. (1989) "Prostaglandin F.sub.2.alpha. Effects on Intraocular Pressure Negatively Correlate with FP-Receptor Stimulation" Invest. Ophthal. 30 (8) 1838-1842.
Supplement to Investigative Ophthalmology and Visual Science 22 39 (1982), L. Z. Bito, A. Draga, J. Blanco, and C. B. Camras, "Maintenance of Reduced Intraocular Pressure (IOP) for several months by topical application of prostaglandin (PG) E.sub.1 to Eyes of Trained Cats".
Abstracts 12 and 13 on p. 325 of ARVO Annual Meeting Abstract Issue 1988 of Annual Mee
Resul Bahram
Stjernschantz Johan W.
Gerstl Robert
Pharmacia Aktiebolag
LandOfFree
Prostaglandin derivatives for the treatment of glaucoma or ocula does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prostaglandin derivatives for the treatment of glaucoma or ocula, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prostaglandin derivatives for the treatment of glaucoma or ocula will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1973472